To be clear, unless its FDA approved its schedule hasn’t changed
There is a certain level of confusion reverberating throughout the cannabis community right now over the DEA’s recent decision to make Epidiolex, the cannabis-based epilepsy drug created by GW Pharmaceuticals, a Schedule V controlled substance. Some folks are convinced that since this FDA-approved medication is pure cannabidiol (CBD) that all CBD products fall into the same category.
Sadly, this is not true. The federal government still considers all other cannabis-derived CBD products to be a violation of federal law.
The DEA’s official statement in the Federal Register, which published Friday, indicates “this order places FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols in schedule V.”
To Read The Rest Of This Article On Forbes, Click Here